His scientific interests lie mostly in Internal medicine, Surgery, Blood pressure, Diabetes mellitus and Type 2 diabetes. His Internal medicine research integrates issues from Placebo and Cardiology. His Surgery research includes elements of Atorvastatin, Cohort study and Risk factor.
His studies deal with areas such as Hemodynamics, Epidemiology and Pediatrics as well as Blood pressure. His work is dedicated to discovering how Diabetes mellitus, Disease are connected with Cognition and other disciplines. His Type 2 diabetes research is multidisciplinary, relying on both Hypoglycemia, Nephropathy, Proportional hazards model, Diabetic angiopathy and Hazard ratio.
His primary areas of investigation include Internal medicine, Blood pressure, Cardiology, Diabetes mellitus and Type 2 diabetes. His Internal medicine research incorporates themes from Placebo, Endocrinology and Surgery. His research investigates the connection between Blood pressure and topics such as Risk factor that intersect with issues in Physical therapy and Epidemiology.
His Cardiology research is multidisciplinary, incorporating perspectives in Amlodipine, Left ventricular hypertrophy, Atenolol and Heart rate. His Diabetes mellitus research is multidisciplinary, incorporating elements of Proportional hazards model and Vascular disease. Type 2 diabetes is closely attributed to Hazard ratio in his work.
The scientist’s investigation covers issues in Blood pressure, Internal medicine, Diabetes mellitus, Emergency medicine and Type 2 diabetes. His Blood pressure study integrates concerns from other disciplines, such as Overweight, Risk factor and Environmental health. He interconnects Liraglutide and Cardiology in the investigation of issues within Internal medicine.
His Liraglutide study combines topics in areas such as Placebo and Insulin. In his work, Creatinine is strongly intertwined with Renal function, which is a subfield of Diabetes mellitus. His Type 2 diabetes research includes themes of Vascular disease and Kidney disease.
Internal medicine, Blood pressure, Diabetes mellitus, Hazard ratio and Placebo are his primary areas of study. His biological study spans a wide range of topics, including Liraglutide, Type 2 diabetes, Type 2 Diabetes Mellitus and Cardiology. His work carried out in the field of Type 2 diabetes brings together such families of science as Proportional hazards model and Insulin.
His work in the fields of Blood pressure, such as Elevated blood, intersects with other areas such as Statistical analysis. He usually deals with Diabetes mellitus and limits it to topics linked to Renal function and Perindopril, Creatinine, Angiotensin-converting enzyme, Renin–angiotensin system and Gastroenterology. The concepts of his Hazard ratio study are interwoven with issues in Albuminuria and Randomized controlled trial.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel;Stephen MacMahon;John Chalmers.
The New England Journal of Medicine (2008)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso;Gilbert H. Daniels;Kirstine Brown-Frandsen;Peter Kristensen.
The New England Journal of Medicine (2016)
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Peter S Sever;Björn Dahlöf;Neil R Poulter;Hans Wedel.
The Lancet (2003)
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.
Kunihiro Matsushita;Marije van der Velde;Brad C. Astor;Mark Woodward.
The Lancet (2010)
2003 European society of hypertension - European Society of Cardiology guidelines for the management of arterial hypertension
G Mancia;EA Rosei;R Cifkova;G DeBacker.
web science (2003)
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
Björn Dahlöf;Peter S Sever;Neil R Poulter;Hans Wedel.
The Lancet (2005)
Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States.
Katharina Wolf-Maier;Richard S. Cooper;José R. Banegas;Simona Giampaoli.
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension.
Peter M Rothwell;Sally C Howard;Eamon Dolan;Eoin O'Brien.
The Lancet (2010)
Hypertension Treatment and Control in Five European Countries, Canada, and the United States
Katharina Wolf-Maier;Richard S. Cooper;Holly Kramer;José R. Banegas.
Interpretation of the evidence for the efficacy and safety of statin therapy.
Rory Collins;Christina Reith;Jonathan Emberson;Jane Armitage.
The Lancet (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: